Qiagen (NYSE:QGEN) Updates FY 2025 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 2.380-2.380 for the period, compared to the consensus earnings per share estimate of 2.360. The company issued revenue guidance of -, compared to the consensus revenue estimate of $2.1 billion. Qiagen also updated its Q4 2025 guidance to 0.600-0.600 EPS.

Qiagen Trading Down 0.1%

Shares of QGEN traded down $0.06 during midday trading on Wednesday, hitting $44.10. The stock had a trading volume of 745,319 shares, compared to its average volume of 1,336,271. Qiagen has a 1 year low of $37.63 and a 1 year high of $51.88. The firm has a market cap of $9.80 billion, a PE ratio of 25.99, a price-to-earnings-growth ratio of 2.48 and a beta of 0.66. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. The stock’s 50 day moving average is $46.66 and its 200 day moving average is $46.48.

Qiagen (NYSE:QGEN) last announced its earnings results on Tuesday, November 4th. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.03. The business had revenue of $533.00 million for the quarter, compared to the consensus estimate of $525.68 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.57 earnings per share. Qiagen has set its FY 2025 guidance at 2.380-2.380 EPS. Q4 2025 guidance at 0.600-0.600 EPS. As a group, analysts forecast that Qiagen will post 2.26 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on QGEN shares. Barclays set a $53.00 price target on shares of Qiagen and gave the company an “overweight” rating in a report on Thursday, October 2nd. UBS Group raised their price target on shares of Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Weiss Ratings restated a “hold (c+)” rating on shares of Qiagen in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Qiagen from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Cowen restated a “hold” rating on shares of Qiagen in a report on Thursday, August 7th. Three investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $49.69.

Institutional Trading of Qiagen

Several institutional investors and hedge funds have recently bought and sold shares of the business. EverSource Wealth Advisors LLC lifted its stake in Qiagen by 226.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock valued at $125,000 after acquiring an additional 1,802 shares during the period. Osaic Holdings Inc. lifted its stake in Qiagen by 101.4% during the 2nd quarter. Osaic Holdings Inc. now owns 3,875 shares of the company’s stock valued at $185,000 after acquiring an additional 1,951 shares during the period. Prudential Financial Inc. lifted its stake in Qiagen by 74.9% during the 2nd quarter. Prudential Financial Inc. now owns 8,873 shares of the company’s stock valued at $426,000 after acquiring an additional 3,799 shares during the period. Pitcairn Co. acquired a new stake in Qiagen during the 2nd quarter valued at approximately $208,000. Finally, Captrust Financial Advisors acquired a new stake in Qiagen during the 2nd quarter valued at approximately $221,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.